Gleevac Infosite 2010 Banner Library

Work log

revised- (7/29/10) revised- (7/12/10) new- (7/6/10)

Gleevac Infosite

Branded Leaderboards

Version 1

KIT+ GIST: Cancer Requiring a Multidisciplinary Approach Gastroenterologists, surgeons, medical oncologists and other healthcare professionals are essential for the diagnosis and co-management of metastatic KIT+ gastrointestinal stromal tumors (GIST)

Important Safety Information Prescribing Information

Learn more

GLEEVEC® (imatinib mesylate) tablets are indicated for:

- Newly diagnosed adult patients with Philadelphia chromosome— positive chronic myeloid leukemia (Ph+ CML) in the chronic phase
 Patients with Ph+ CML in blast crisis (BC), accelerated phase
- (AP), or in the chronic phase (CP) after failure of interferon-alpha Adult patients with relapsed of refractory Philadelphia.

Version 2

Tyrosine kinase inhibitors (TKIs) may improve outcomes in patients with KIT+ gastrointestinal stromal tumors (GIST)

Important Safety Information Prescribing Information

> View efficacy data on

GLEEVEC® (imatinib mesylate) tablets are indicated for

- · Newly diagnosed adult patients with Philadelphia chromosome-
- positive chronic myeloid leukemia (Ph+ CML) in the chronic phase Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.
- nts with relansed of refractory Philade

Version 3

Review the safety profile of an oral tyrosine kinase inhibitor (TKI) approved for metastatic, unresectable KIT+ gastrointestinal stromal tumors (GIST)

Important Safety Information Prescribing Information

View safety data

GLEEVEC® (imatinib mesylate) tablets are indicated for:

Newly diagnosed adult patients with Philadelphia chromosome-

- positive chronic myeloid leukemia (Ph+ CML) in the chronic phase Patients with Ph+ CML in blast crisis (BC), accelerated phase
- (AP), or in the chronic phase (CP) after failure of interferon-alpha

Version 4

KIT+ Gastrointestinal Stromal Tumors (GIST):Important Safety Dose escalation of GLEEVEC® (imatinib mesylate) may offer a clinical benefit to patients with unresectable and/or metastatic KIT+ GIST

- experiencing disease progression Important Safety Information Prescribing Information

Can it optimize outcomes?

- GLEEVEC® (imatinib mesulate) tablets are indicated for Newly diagnosed adult patients with Philadelphia chromosome— positive chronic myeloid leukemia (Ph+ CML) in the chronic phase
- Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha
- therapy.

 Adult patients with relapsed of refractory Philadelphia.

Version 5

The Only Therapy Approved for First-Line Use in Metastatic KIT+ GastroIntestinal Stromal Tumors (GIST) Review response rates and tumor control data for an oral tyrosine kinas nhibitor (TKI) used in patients with KIT+ GIST

View efficacy data

- Important Safety Information Prescribing Informati
- GLEEVEC® (imatinib mesylate) tablets are indicated for
- Newly diagnosed adult patients with Philadelphia chromosome—
 positive chronic myeloid leukemia (Ph+ CML) in the chronic phase
 Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.
- Adult natients with relansed of refractory Philadelphia

A Patient Case Showing the Potential for Misdiagnosis in KIT+

GIST

Initial CT scans indicate ovarian carcinoma: a multidisciplinary team coordinates to properly diagnose KIT+ gastrointestinal stromal tumors (GIST)

A GISTexchange patient case

- Important Safety Information
- GLEEVEC® (imatinib mesylate) tablets are indicated for
- Newly diagnosed adult patients with Philadelphia chromosome— positive chronic myeloid leukemia (Ph+ CML) in the chronic phase
 Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha
- therapy.
 Adult natients with relansed of refractory Philadelphia

Version 7

Learn more

Prescribing Information

- GLEEVEC® (imatinib mesylate) tablets are indicated for:

 Newly diagnosed adult patients with Philadelphia chromosome
 - positive chronic myeloid leukemia (Ph+ CML) in the chronic phase Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha

Version 8

A Treatment Option for 5 Distinct and Potentially Life-Threatening Rare Diseases Review clinical data supporting the use of an oral tyrosine kinase inhibitor (TKI) used for treatment of these Rare Diseases

- Important Safety Information
- Prescribing Information
- GLEEVEC® (imatinib mesylate) tablets are indicated for:

 Newly diagnosed adult patients with Philadelphia chromosome—
 positive chronic myeloid leukemia (Ph. CML) in the chronic phase
 Patients with Ph. CML in blast crisis (BC), accelerated phase
 (AP), or in the chronic phase (CP) after failure of interferon-alpha
 - therapy.

Branded Squareboys

Version 1

KIT+ GIST: Cancer Requiring a Multidisciplinary Gastroenterologists, surgeons, medical oncologists and other healthcare professionals are essential for the diagnosis and co-management of metastatic KIT+ gastrointestinal stromal tumors (GIST) Learn more Important Safety Information Prescribing Information GLEEVEC® (imatinib mesylate) tablets are indicated for:

- Newly diagnosed adult patients with Philadelphia chromosome–positive chronic myeloid leukemia
- (Ph+ CML) in the chronic phase.

 Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

 Adult patients with relapsed of refractory Philadelphia

Version 3

Review the safety profile of an oral tyrosine kinase inhibitor (TKI) approved for metastatic, unres KIT+ gastrointestinal stromal tumors (GIST) View safety data Important Safety Information Prescribing Information

GLEEVEC® (imatinib mesylate) tablets are indicated for:

Newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. • Patients with Ph+ CML in blast crisis (BC),

accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

Version 4

KIT+ Gastrointestinal Stromal Tumors (GIST): Dose escalation of GLEEVEC® (imatinib mesylate) may offer a clinical benefit to patients with unresectable and/or metastatic KIT+ GIST experiencing disease progression Can it optimize outcomes? Important Safety Information Prescribing Information GLEEVEC® (imatinib mesylate) tablets are indicated for: · Newly diagnosed adult patients with Philadelphia

chromosome—positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. • Patients with Ph+ CML in blast crisis (BC),

accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

Adult patients with relapsed of refractory Philadelphia chromosome positive acute lymphoblastic leukemia

Version 5

The Only Therapy Approved for First-Line Use in Metastatic KIT+ Gastrointestinal Stromal Tumors

Review response rates and tumor control data for an oral tyrosine kinase inhibitor (TKI) used in patients with KIT+ GIST

Important Safety Information • Prescribing Information

GLEEVEC® (imatinib mesylate) tablets are indicated for: · Newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. • Patients with Ph+ CML in blast crisis (BC),

accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

Adult patients with relapsed of refractory Philadelphia
 chromosome positive as the home philadelphia

Version 6

A Patient Case Showing the Potential for Misdiagnosis in KIT+ GIST Initial CT scans indicate ovarian carcinoma: a multidisciplinary team coordinates to properly diagnose KIT+ gastrointestinal stromal tumors (GIST)

3 A GISTexchange patient case

Important Safety Information • Prescribing Informati GLEEVEC® (imatinib mesylate) tablets are indicated for:

· Newly diagnosed adult patients with Philadelphia

Newy diagnosed adult patients with Philadelphia chromosome—positive chronic myeloid leukemia (Ph+ CML) in the chronic phase.
 Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

Adult patients with relapsed of refractory Philadelphia

Version 7

Important Safety Information • Prescribing Information

- GLEEVEC® (imatinib mesylate) tablets are indicated for:

 Newly diagnosed adult patients with Philadelphia chromosome—positive chronic myeloid leukemia (Ph+ CML) in the chronic phase.

 Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

 Adult patients with relapsed of refractory Philadelphia

Version 8

A Treatment Option for 5 Distinct and Potentially Life-Threatening Rare Diseases
Review clinical data supporting the use of an oral tyrosine kinase inhibitor (TKI) used for treatment of these Rare Diseases

Important Safety Information • Prescribing Information

- GLEEVEC® (imatinib mesylate) tablets are indicated for:

 Newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase.

 Patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy.

 Adult patients with relapsed of refractory Philadelphia chromosome positive acute hymphoblastic laukemia.